Policy Notices

• Notice of Update to the Reporting Period of the Annual Report to OLAW
  (NOT-OD-20-109)
  National Institutes of Health
  

• Reissue of Parent Announcements (PA-18-589, PA-18-590, PA-18-591, and PA-18-592) and the Urgent (PA-18-935) and Emergency (PA-20-135) Competitive Revision FOAs is Underway - Continue to use the Current Announcements and Forms Packages Until Reissuance
  (NOT-OD-20-110)
  National Institutes of Health
  

General Notices

• NICHD Late Application Policy for Institutional Training Grants to RFA-HD-21-014 Due to Public Health Emergency for United States Coronavirus Disease 2019 (COVID-19)
  (NOT-HD-20-016)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  

• NHLBI Announces Availability of Frequently Asked Questions (FAQs) for PAR-19-329 and PAR-19-330: Multi-Site Investigator-Initiated Clinical Trials
  (NOT-HL-20-792)
  National Heart, Lung, and Blood Institute
  

• Request for Information: Use of Cloud Resources and New File Formats for Sequence Read Archive Data
  (NOT-OD-20-108)
  National Institutes of Health
  

• Request for Information (RFI): Input on Improvements to the Illuminating the Druggable Genome (IDG) Programs Digital Resources
  (NOT-RM-20-018)
  Office of Strategic Coordination (Common Fund)
  

Notice of Changes to Funding Opportunities

• Notice of Early Expiration of Notice of Special Interest (NOSI): Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)," NOT-AI-20-031
  (NOT-AI-20-050)
  National Institute of Allergy and Infectious Diseases
  

• Notice of Clarification to Eligibility Information in RFA-AI-20-023 Limited Competition: International Epidemiology Databases to Evaluate AIDS (IeDEA) (U01 Clinical Trial Not Allowed)
  (NOT-AI-20-052)
  National Institute of Allergy and Infectious Diseases
  

• Notice of Change: Late Application Policy for June 17, 2020, Application Due Date of PAR-19-242, Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional) Due to Public Health Emergency for US Coronavirus Disease 2019
  (NOT-CA-20-069)
  National Cancer Institute
  

• Notice of NIDCD's Withdrawal from Participation in PA-20-183 "Research Project Grant (Parent R01 Clinical Trial Required)"
  (NOT-DC-20-009)
  National Institute on Deafness and Other Communication Disorders
  

• Notice of Change in Application Due Date for PAR-19-215 Due to Public Health Emergency for United States Coronavirus Disease 2019 (COVID-19)
  (NOT-EB-20-012)
  National Institute of Biomedical Imaging and Bioengineering
  

• RESCINDED - NHGRI Late Application Policy for NHGRI-Specific FOAs with Application Due Dates in May, June, and July
  (NOT-HG-20-041)
  National Human Genome Research Institute
  

Notices of Special Interest

• Notice of Special Interest (NOSI): Select Research Areas for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)
  (NOT-AI-20-051)
  National Institute of Allergy and Infectious Diseases
  

• Notice of Special Interest (NOSI): Improving Outcomes for Disorders of Human Communication
  (NOT-DC-20-007)
  National Institute on Deafness and Other Communication Disorders
  

• Notice of Special Interest (NOSI): Administrative Supplements to Existing R01 Grants on Polycystic Kidney Disease (PKD)
  (NOT-DK-20-031)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Notice of Special Interest (NOSI): Development and Preliminary Testing of Health-related Behavioral Interventions
  (NOT-OD-20-106)
  Office of Behavioral and Social Sciences Research
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Institute on Aging
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute of Mental Health
  National Institute of Nursing Research
  

Funding Opportunities

• Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products (Collaborative UG3/UH3 Clinical Trial Required)
  (PAR-20-215)
  National Center for Complementary and Integrative Health
  Application Receipt Date(s): New Applications: July 20,2020; February 01, 2021; October 01, 2021; June 01, 2022; February 01, 2023 Revision, Resubmission Applications: July 20, 2020; February 17, 2021; October 15, 2021; June 15, 2022; February 15, 2023
  
  

• NCCIH Natural Product Mid Phase Clinical Trial Cooperative Agreement (U01 Clinical Trial Required)
  (PAR-20-216)
  National Center for Complementary and Integrative Health
  Application Receipt Date(s): New Applications: July 20,2020; February 01, 2021; October 01, 2021; June 01, 2022; February 01, 2023 Resubmission and Revision: July 20, 2020; February 17, 2021; October 15, 2021; June 15, 2022; February 15, 2023
  
  

• NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
  (PAR-20-217)
  National Center for Complementary and Integrative Health
  Office of Dietary Supplements
  Application Receipt Date(s): New Applications: July 20,2020; February 01, 2021; October 01, 2021; June 01, 2022; February 01, 2023 Resubmission Applications: July 20, 2020; February 17, 2021; October 15, 2021; June 15, 2022; February 15, 2023
  
  

• NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
  (PAR-20-218)
  National Center for Complementary and Integrative Health
  Office of Dietary Supplements
  Application Receipt Date(s): New Applications: July 20,2020; February 01, 2021; October 01, 2021; June 01, 2022; February 01, 2023 Resubmission Applications: July 20, 2020; February 17, 2021; October 15, 2021; June 15, 2022; February 15, 2023
  
  

• Natural Product Multi-Site Clinical Trial Data Coordinating Center (Collaborative U24 Clinical Trial Required)
  (PAR-20-219)
  National Center for Complementary and Integrative Health
  Application Receipt Date(s): New Applications: July 20,2020; February 01, 2021; October 01, 2021; June 01, 2022; February 01, 2023 ,Resubmission and Revision Applications: July 20, 2020; February 17, 2021; October 15, 2021; June 15, 2022; February 15, 2023
  
  

• NIDDK Centers for Diabetes Translation Research (P30 Clinical Trial Optional)
  (RFA-DK-20-002)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): October 20, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• SBIR E-Learning for HAZMAT and Emergency Response (R43/R44 Clinical Trial Not Allowed)
  (RFA-ES-20-012)
  National Institute of Environmental Health Sciences
  Application Receipt Date(s): August 10, 2020
  
  

• Elucidating the Role of Nutrition in Care and Development of Preterm Infants (R01 Clinical Trial Optional)
  (RFA-HD-21-006)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): November 30, 2020
  
  

• NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)
  (RFA-RM-20-011)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): September 11, 2020. No late applications will be accepted for this Funding Opportunity Announcement.
  
  

• NIH Directors New Innovator Award Program (DP2 Clinical Trial Optional)
  (RFA-RM-20-012)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): August 21, 2020 No late applications will be accepted for this Funding Opportunity Announcement. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• NIH Directors Transformative Research Awards (R01 Clinical Trial Optional)
  (RFA-RM-20-013)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): September 30, 2020 No late applications will be accepted for this Funding Opportunity Announcement.
  
  

• NIH Directors Early Independence Awards (DP5 Clinical Trial Optional)
  (RFA-RM-20-014)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): September 4, 2020 No late applications will be accepted for this Funding Opportunity Announcement.
  
  

• NIH Directors Emergency Transformative Research Awards (R01 Clinical Trial Optional)
  (RFA-RM-20-020)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): September 30, 2020 No late applications will be accepted for this Funding Opportunity Announcement.
  
  

• NIH Directors Emergency Early Independence Awards (DP5 Clinical Trial Optional)
  (RFA-RM-20-021)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): September 4, 2020 No late applications will be accepted for this Funding Opportunity Announcement.